Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma

NCT05022901 is registered in ClinicalTrials.gov with Delcath Systems Inc. as lead sponsor.

NCT NCT05022901
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05022901 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma
Lead sponsor
Delcath Systems Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 10, 2022
Completion date
March 1, 2024
Enrollment
30 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic ocular melanoma, metastatic uveal melanoma